SRX 3225

Drug Profile

SRX 3225

Alternative Names: BRD4/HDAC6/PI3K Triple Inhibitor - SignalRx; HDAC6/BRD4/PI3K Triple Inhibitor - SignalRx; PI3K/BRD4/HDAC6 Triple Inhibitor - SignalRx; SRX3225

Latest Information Update: 17 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SignalRx Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; BRD4-protein-inhibitors; HDAC6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 04 Jan 2018 SRX 3225 is available for licensing as of 04 Jan 2018.
  • 04 Jan 2018 Early research in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top